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Summary
Activating Transcription Factor-2 is a sequence-specific
DNA-binding protein that belongs to the bZIP family of
proteins and plays diverse roles in the mammalian cells.
In response to stress stimuli, it activates a variety of gene
targets including cyclin A, cyclin D and c-jun, which are
involved in oncogenesis in various tissue types. ATF-2
expression has been correlated with maintenance of a
cancer cell phenotype. However, other studies demon-
strate an antiproliferative or apoptotic role for ATF-2. In
this review, we summarize the signaling pathways that
activate ATF-2, as well as its downstream targets. We
examine the role of ATF-2 in carcinogenesis with respect
to other bZIP proteins, using data from studies in human
cancer cell lines, human tumours and mouse models, and
we propose a potential model for its function in carcino-
genesis, as well as a theoretical basis for its utility
in anticancer drug design. BioEssays 30:314–327,
2008.  2008 Wiley Periodicals, Inc.
Introduction
Tumourigenesis is considered to be a multistep process.
These steps reflect genetic and epigenetic alterations that
result in progressive conversion of a normal human cell into a
highly malignant one. Animal models and human cancer
studies indicate that tumour development proceeds through a
process analogous to Darwinian evolution, in which ‘‘success-
ful’’ genetic changes offer a growth advantage to normal cells,
leading to their progressive transformation into cancer cells.
For a cancer phenotype to develop, the normal cell progres-
sively acquires certain capabilities such as self sufficiency in
growth signals, insensitivity to anti-growth signals, unlimited
replicative potential, evading apoptosis, sustained angio-
genesis, as well as tissue invasion and metastasis.(1)
Since in situ studies in human material are not sufficient to
elucidate the mechanisms underlying the sequential events
of the carcinogenetic process, both animal and cancer cell
line models have been recruited in order to complement the
studies of human pre-malignant and malignant regions.
Perhaps the most popular tumourigenesis study models are
the mouse models. Mouse models have often been invaluable
in understanding several topics of human carcinogenesis and,
most importantly, in contrast to cell models, they provide in vivo
rather than in vitro information for tumour development,
metastasis and testing of anticancer drugs.(2)
Recent studies implicate the ATF/CREB family of tran-
scription factors in cancer progression.(3,4) The ATF/CREB
family is a large group of bZIP transcription factors which,
despite their diverse physiological roles, all share the ability to
respond to environmental signals and maintain cellular
homeostasis.(5) Mounting evidence indicates a dynamic role
for the ATF/CREB family member ATF-2 invarious steps of the
carcinogenetic process. The ATF-2 (or CREB-BP1) gene is
located on human chromosome 2q32 and encodes a 505 aa
protein (see Fig. 1).(6) Studies on ATF-2-deficient mice reveal
an essential role in skeletal and central nervous system
development, and for maximal induction of genes with CRE
sites.(7) Our previous work with the mouse skin carcinogenesis
model has revealed a role of the ATF/CREB family member
ATF-2 in growth and progression of mouse skin tumours.(8,9) In
this review, we summarize the signals that activate ATF-2 as
well as the downstream targets of ATF-2 and we examine its
role in human tumours, cancer cell lines and animal models.
We exploit these pieces of information to come up with a model
for the action of ATF-2 in carcinogenesis. We also highlight
possible strategies for targeting against ATF-2, for future ATF-
2-based anticancer drug design.
ATF/CREB family proteins are
implicated in cancer
The mammalian ATF/CREB family consists of sixteen cellular
stress-responsive transcription factors, divided into six sub-
groups, according to their sequence similarity.(5,10–12) The
common feature that all these proteins share is the bZIP
element, through which they can both dimerize and bind to
specific DNA sequences (see Fig. 2).(10–19) The bZIP element
consists of a leucine zipper subdomain and a basic region
subdomain that are connected by a short fork.(20) ATF/CREB
family proteins not only homodimerize, but also selectively
heterodimerize with each other.(21,22) However, they do
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not share much similarity other than the bZIP domain
and their ability to bind to the ATF/CRE consensus
TGACGTCA
G
A.
(21,23)
Many family members are positivelyassociated with cancer
progression. For example, ATF-1 acts as a survival factor for
human melanoma cells(24) and promotes tumour invasiveness
of thyroid papillarycarcinoma.(25) ATF-4 overexpression offers
drug resistance to human cancer cell lines.(26) CREB
phosphorylation enhances tumour survival of human lung
cancer cell lines.(27) ATF-6 overexpression is implicated in
hepatocarcinogenesis,(28) while ATF-5 has been suggested to
have an anti-apoptotic role.(29)
However, other members of the family present both positive
and negative involvement in cell survival. On the one hand,
ATF-3 overexpression promotes invasiveness of prostate
tumour cells(30) but, on the other hand, it has been
characterized as a putative anti-tumourigenic gene in ovary
cancer.(31) There are also conflicting reports about the role of
ATF-2 in cancer. Recent reports demonstrate that ATF-2
overexpression enhances cell proliferation both in human(4,32)
and in mouse(9) cancer cell lines. In contrast are the findings of
a report showing that reduced levels of ATF-2 predispose mice
to mammary tumours.(33) This review, for the first time, sheds
light on the actual role of ATF-2 in cancer.
Signals activating ATF-2
ATF-2containsSp1elementsandaCRE-likeelement inpromoter
region50 toþ90 that seems to be important for basal promoter
activity;(34) however its activation is basically achieved through
posttranslational modifications, upon stress stimulus. In unstimu-
lated cells, ATF-2 is maintained in a transcriptionally inactive form
by intramolecular interactions between its own activation domain
and its bZIP domain.(35) In response to stress stimuli(36–42) the
Ras-activatedsignalcascadesp38andJNKphosphorylateATF-2
protein at amino acids Thr69 and Thr71.(36,37) The Ras effector
pathway Raf-MEK-ERK also acts synergistically with the Ral-
RalGDS-Src-p38 pathway in a two-step ATF-2 phosphorylation,
where the former phosphorylates Thr71, while the latter
phosphorylates Thr69.(43)
Phosphorylated ATF-2 forms dimers that bind to specific
DNA sequences on target gene promoters, activating
their expression. ATF-2 can form homodimers or selective
heterodimers with other members of the ATF/CREB family
(see Table 1)(10,12,16,19,21,44–52) and Fos/Jun family (see
Table 2).(3,16,19,45,49,51–59) Typically, ATF-2 dimers bind pre-
ferentially to the 8-base palindromic CRE (cAMP Responsive
Element) consensus sequence TGTACGTCA on target gene
promoters, that responds to elevated cAMP.(21,60) However,
ATF-2 has also been shown to bind to other elements, such as
Figure 1. A: ATF-2 gene organization. The ATF-2 consists of 12 exons and it is translated to a 505 aa protein. The bZIP protein domain
corresponds to parts of exon 10 and exon 11 of ATF-2 gene. B:ATF-2 dimer formation. ATF-2 forms homodimers or heterodimerswith other
b-ZIP proteins.
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the AP-1 element,(61,62) the proximal element of IFN-g
promoter,(63) the stress-response element (StRE) of ho-1
gene,(64) and the UV-Responsive Element (URE).(4)
Although only few Ras-promoted pathways lead to ATF-2
activation, the ability of ATF-2 to form homodimers and a wide
range of selective heterodimers, as well as to bind to more than
one type of responsive elements, may offer ATF-2 a certain
degree of functional plasticity, resulting in the activation of a
variety of target genes.
ATF-2 activates target genes involved in cancer
Activated ATF-2 complexes stimulate a broad spectrum of
targets that are implicated in cancer (see Fig. 3):
Cell-cycle molecules
cyclin D1, an important gene for the integration of proliferative
and antiproliferative signals during the G1 phase of the cell
cycle, possesses a CRE element within its promoter region. In
mouse chondrocytes, cyclin D1 is directly activated by ATF-2,
while the levels of activation are reduced in ATF-2-deficient
mice.(65) cyclin D1 activation by ATF-2 has also been
demonstrated in proliferating mouse melanoma cells.(66)
Similarly, cyclin A plays an essential role in S phase
progression. In mouse chondrocytes, serum-activated ATF-2
promotes Cyclin A expression by binding a CRE-responsive
element located in the promoter of cyclin A, whereas the exact
opposite is observed in ATF-2-deficient mice.(39)
Molecules related with invasion
The promoter of MMP-2, a matrix metalloproteinase capable
of degrading all components of the extracellular matrix,
possesses an ATF-2-responsive AP-1 element.(61) In addition,
urokinase Plasminogen Activator (uPA), an enzyme neces-
sary for the degradation of a variety of extracellular proteins
that connect cells to the extracellular matrix, used as a
prognostic marker in various malignancies,(67) responds to
c-Jun–ATF-2 heterodimers that bind to an AP-1 element on its
gene promoter.(62)
Growth factors/receptors—cytokines
Platelet-derived growth factor receptor a (PDGFR a) is a
growth-regulatory protein that has been characterized as an
ATF-2 target in mice. In cytotrophoblast cells from ATF-2 null
mice placenta, PDGFRa is downregulated compared to ATF-2
wild-type mice.(68) In addition IL-8, a chemokine involved in
epithelial–mesenchymal transition of colon carcinoma,(69) is
responsive to p38-activated ATF2–c-Jun heterodimers that
bind to AP-1 sites located in the IL-8 promoter.(70)
Figure 2. ATF/CREB family proteins. The protein members can be grouped in six subgroups, according to their sequence similarity. The
red boxes indicate the bZIP domain. (See references 10–19 and GenBank Accession numbers: AAC60616, Q02930, AAC02258, P18848,
AAD51372, AAB49921).
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Table 2. Dimer formation between ATF/CREB and Fos/Jun family members (interfamily dimerization)
JUN FAMILY PROTEINS
FOS FAMILY PROTEINS
c-Jun JunB JunD c-Fos FosB Fra-1 Fra-2
ATF-1 53 52 53
ATF-2 þ53 þ58 þ53 53 þ55
ATF-3 þ52 þ52 þ56,52 51/þ59 þ59 52
ATF3b
ATF-4 þ53 þ56 þ53 þ52 þ53
ATF-5
ATF6a
ATF6b
ATFa þ57 þ52 þ52 þ57
ATF-a0
B-ATF þ3,19 þ3,19 þ3,19 19
CREB 49 52
CREM 54 54
CRE-BPa þ16
JDP-1 þ45
JDP-2 þ45
þ: dimer formation.
: dimer formation is not possible.
Figure 3. ATF-2 phosphorylation and activation of its downstream targets. Various stress stimuli activate the p38 or/and JNK pathways,
which phosphorylate ATF-2. Phosphorylated ATF-2 forms homodimers or selective heterodimers, activating a varietyof gene targets, many
of which are implicated in processes that are deregulated in cancer, including c-jun. Newly synthesized c-Jun dimerizes with ATF-2,
reinforcing transcription of ATF-2 gene targets.
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Cell adhesion molecules
E-selectin seems to play a role in transendothelial migration of
cancerous cells.(71) In endothelial cells, an ATF-2–c-Jun
heterodimer is constitutively bound to a CRE-like sequence
of the E-selectin promoter. Upon TNF-a stimulation, ATF-2
and c-Jun are phosphorylated by the MAP kinases JNK and
p38 and co-operate with NF-kB in activating E-selectin
transcription.(72)
Anti-apoptotic factors
bcl-2, one of the most-potent inhibitors of apoptosis, contains a
CRE element responsive to ATF-2 in its promoter region.(73)
ATF-2 activates its bZIP-binding partners
c-jun transcription factor represents a special gene target of
ATF-2, as it is both a target and a co-operator of ATF-2. c-Jun is
a bZIP protein, which belongs to the Jun protein family.
Through its bZIP domain, it forms either homodimers or
heterodimers with other members of the Jun family (c-Jun–
JunB, c-Jun–JunD heterodimers), as well as heterodimers
with Fos family members. The dimers that Jun members form
are called AP-1 proteins and bind to the AP-1 element located
in numerous genes (reviewed in Ref. 123). Jun–Jun and Jun–
Fos dimers activate transcription of target genes by binding to
the 7-base classical pseudopalindromic AP-1 consensus
sequence TGTA
C
GTCA, in contrast to the 8-base palindromic
CRE consensus sequence TGTACGTCA that ATF-2–Jun
heterodimers prefer to bind.(53,59,75)
The c-jun promoter carries two relatively similar AP-1-
binding sites, jun1TRE (the one closest to the transcription
start site) and jun2TRE (the one distal from the transcription
start site), which resemble both ‘‘classical’’ AP-1 and ATF/
CREB-binding sites. jun2TRE and, to a lesser extent, jun1TRE
can bind c-Jun–ATF-2 heterodimers. In detail, a number of
stress stimuli activate JNK–SAPK (Stress Activated Protein
Kinases), which phosphorylate both ATF-2 (on Thr69 and
Thr71) and c-Jun (on Ser63 and Ser73), thus enabling the
heterodimer formation. The initial c-Jun–ATF-2 heterodimer
enhances c-jun transcription via binding to the jun2TRE
element.(76,77) c-Jun can also be de novo synthesized in
response to other stimuli, such as PDGF, serum and phorbol
esters, via the ERK pathway, however ATF-2 is not involved in
this process; rather, ERK (Extracellular-Regulated Kinase)
stimulates Jun–Fos dimer formation (reviewed in Ref. (78).
Moreover, ATF-2 activates the ATF/CREB family member
ATF-3, a transcription factor with a highly controversial role
in cancer. The ATF-3 promoter contains both AP-1- and
CRE-binding sites and responds to c-jun–ATF-2 complexes
activated by the JNK–SAPK signal transduction pathway.(79)
ATF-3 promotes cell cycle arrest and apoptosis by repressing
cyclin D1 transcription in Ras-stimulated mouse fibroblasts, a
widely accepted model for studying Ras-stimulated tumouri-
genesis,(80) while it activates p53 by inhibiting its ubiquitination
in the same study model.(81) In contrast to the above anti-
proliferative role, overexpression of ATF-3 activates cyclin D1
promoter, when AP-1 and CRE elements of ATF-3 promoter
remain intact, thus enhancing cyclin D1 expression in the Hepa
1–6 mouse hepatoma cell line.(82) Since it has not been
clarified whether ATF-3 transcription is activated via the AP-1
or/and the CRE element, the opposing effects of ATF-3 could
be attributed to differential accumulation of these crucial
elements in response to different stress stimuli, as well as to its
combination with different bZIP-binding partners.
As described above, ATF-2 regulates transcription of ATF/
CREB and Jun/Fos family members. Other ATF/CREB family
members present similar behavior, since CREB activates c-fos
transcription via a CRE element on c-fos gene promoter, while
CREM antagonizes the activating function of CREB, by
forming inactive CREB–CREM heterodimers.(44) Further-
more, both CREB and CREM dimers block c-jun transcription
by binding to the TRE responsive element.(54) Perhaps,
regulation of Jun/Fos proteins by ATF/CREB proteins repre-
sents a general mechanism of regulating bZIP proteins’
selective dimerizations and interactions. It is possible that
ATF-2 per se is regulated by other members of ATF/CREB
family, since it possesses two CRE-like binding sites, one of
which is located in a region significant for basal promoter
activity.(34) However, it is of note that, among ATF/CREB family
members, only ATF-2 seems to have the ability to activate two
of its bZIP partners (see Table 1, Table 2). This exclusive
characteristic implies that ATF-2 is a potential dynamic
modifier of bZIP interactions and may drastically affect bZIP
protein interactions in oncogenesis.
Interactions of ATF-2 with
c-Jun in oncogenesis
ATF-2–c-Jun seems to be a common dimer in oncogenetic
processes. Promoter array hybridization experiments in the
human breast carcinoma cell line BT474 revealed that, upon
genotoxic stress and subsequent JNK activation, c-jun–ATF-2
dimers could target 121 genes, including 10 that were
implicated in the DNA repair process, activating their
expression (see Fig. 3). c-Jun and ATF-2 interacted with the
targets as complexes with discrete compositions, either as
homodimers or as heterodimers, with the most common
composition being that of c-Jun–ATF-2 heterodimers.(41)
ATF-2 seems to act as an important modifier of the dynamic
balance between c-Jun and the other members of the Jun
family, JunB and JunD. Their interactions affect cell cycle
progression since, upon Ras stimulation, c-Jun induces G1–S
transition by activating crucial cell cycle regulators (cdk4/6,
cyclin D1), whereas JunB and JunD have opposite effects
(reviewed in Ref. (74)) By inducing c-Jun expression or/and by
forming selective heterodimers with c-Jun and JunD (see Table
2), ATF-2 is indirectly involved in this antagonism. Alterations in
ATF-2 activity, either by active ATF-2 mutants(83) or dominant
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negative ones,(84) could result in c-Jun level alterations and,
eventually, deregulation of cell cycle progression.
The binding partner of c-Jun in the AP-1 complex seems to
affect its behavior in carcinogenesis. The decision of a cell to
proliferate, differentiate or die by apoptosis depends on the
composition of the AP-1 complex, as well as the cell lineage,
the differentiation stage, the microenvironment and the type of
stimulus (reviewed in Ref. 85). For example, in the human
leukemia cell line HL60, AP-1 complex components change
during 1,25-dihydroxyvitamin D3-induced differentiation. Spe-
cifically, AP-1 components in the early stage of differentiation
include c-Jun, ATF-2, FosB, Fra-1 and Fra-2, whereas AP-1
components in cells with a more-established monocytic
phenotype include c-Jun, ATF-2 and FosB.(86) In addition,
in vitro studies in chicken embryo fibroblasts have revealed
that when ATF-2 is the partner of c-Jun, then growth-factor
independence is induced, but not anchorage-independence
growth, whereas the opposite exists when c-Fos is the partner
of c-Jun.(87) Perhaps, dimerization of ATF-2 with c-Jun results
in the activation of CRE-responsive genes rather than AP-1-
responsive genes and to subsequent alterations in the
processes in which these genes are involved. ATF-2 could
modify AP-1 carcinogenetic effects, not only by regulating
c-jun transcription, but also by forming selective heterodimers
and changing AP-1 composition, thus re-orientating c-Jun to
CRE targets rather than AP-1 targets. If this hypothesis holds
true, a single nucleotide between the 7-base AP-1 and the
8-base CRE elements makes the difference!?
Interactions of ATF-2 with other
bZIP proteins in oncogenesis
In many cases, together with ATF-2, other bZIP family
members drastically affect ATF-2 regulatory function in many
ways within the cancerous environment. First of all, other ATF/
CREB family members seem to inhibit ATF-2 function, not
through antagonism for binding to CRE-responsive genes, but
by taking advantage of the selective dimerization character-
istic, in order to inhibit its binding to target gene promoters. For
example, the rat cyclin A CRE element responds to ATF-2 and
JunD. Notably, ATF-4 co-expression suppresses activation of
the cyclin A promoter by ATF-2 and Jun family members,
implying that an antagonistic relationship exists between ATF-
2 and ATF-4 for Jun binding, which possibly results in inhibition
of ATF-2–JunD heterodimerization.(58) Consistent with this
idea, JDP-2 forms inactive heterodimers with ATF-2 as well as
c-Jun, thus suppressing CRE and AP-1 target gene tran-
scription correspondingly.(45,48) This type of interaction seems
to be general for bZIP proteins, rather than ATF-2 exclusive,
because the ATF/CREB family member B-ATF competes with
c-Fos for c-Jun binding, resulting in transcriptionally inert Jun–
B-ATF heterodimer formation and reduced cell growth rate in
mouse study fibroblast cells.(3)
An additional type of ATF-2 interaction with other bZIP
proteins in oncogenesis could be the antagonism between
bZIP dimers for binding to the same promoter region, leading
to either activation or inhibition of gene transcription via the
same binding site. For example, in the hepatocarcinoma cell
line HepG2, ATF-2 is a positive regulator of ApoCIII, upon TNF-
a stimulation, whereas the Jun family members (c-Jun, JunB
and JunD) repress ApoCIII through the same promoter region
in a dose-dependent manner.(88) Activation of IFN gamma
(IFN-g), a gene known to prevent the development of primary
and transplanted tumours, represents a more complex
paradigm: the IFN-g promoter possesses a composite
regulatory element (proximal element) responsive to the
transcription factors ATF-1, ATF-2, c-Jun and other Jun
proteins, CREB and Oct-1. In unstimulated T cells, CREB,
ATF-1, ATF-2 and Jun family proteins, other than c-Jun, are
present, whereas in stimulated Tcells a shift to phosphorylated
c-Jun–ATF-2 dimers occurs.(63) An antagonism for binding
between bZIP dimers seems to take place on the IFN-g
proximal element, because CREB homodimers or/and
CREB–ATF-1 heterodimers antagonize Jun dimers for bind-
ing to this element. Alteration of the balance among these
molecules, as well as their unphosphorylated forms, upon
stress stimuli, results in activation or inhibition of IFN-g
transcription.
Alternatively, multiple bZIP proteins, including ATF-2 may
not antagonize, but co-operate for the transcriptional activa-
tion of a target gene. Notably, in the human hepatocarcinoma
cell line Hepa, the ho-1 gene, which catalyzes the first and rate-
limiting step in heme catabolism, possesses a stress-
response element (StRE), responsive not only to ATF-2, but
also to a number of other bZIP proteins (ATF-3, FosB, JunB
and JunD).(64) Multiple dimer complexes among the above
mentioned proteins could act either synergistically or equiv-
alently for the activation of this gene.
Finally, ATF-2-containing complexes may have the ability to
select between different types of binding elements, resulting in
the activation of different subsets of target genes and,
therefore, to expression of different cancer cell phenotypes.
Specifically, in apoptotic rat C6 glioma cells the complexes,
which comprise phosphorylated c-Jun, phosphorylated ATF-
2, JunB and JunD, trans-activate FasL promoters, while in
pro-apoptotic cells different bZIP protein composition results
in selection of AP-1/TRE promoters.(89)
Altogether, it seems that a fine-tuned network of interacting
bZIP proteins, including ATF-2, rather than a specific
homodimer or heterodimer is involved in response to cellular
stress stimuli. Interactions between ATF-2 and bZIP proteins
involve a) regulation of other bZIP proteins’ transcription,
(b) antagonism with other bZIP monomers for selective dimer
formation, (c) antagonism between bZIP dimers for binding to
the same responsive element (d) co-operation or equivalency
between bZIP dimers for binding to the same responsive
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element,and (e) selection of the responsive element according
to the overall cellular bZIP content. Deregulation of one or
more of these types of interaction might cause alterations in
processes such as proliferation, differentiation and apoptosis,
thus leading to acquisition of cancerous characteristics.
Additional parameters in the cell environment, e.g. the type
of stress stimulus and the cell type may also play a role in the
overall ATF-2 effect in oncogenesis. It is possible that other
bZIP proteins could act through one or more of these types of
interaction during oncogenesis. However, the fact that ATF-2 is
implicated in all these types of interaction that affect target
gene regulation makes it a potential dynamic modifier of the
bZIP proteins’ balance and thus a major modulator of the cell
fate (see Fig. 4).
The role of ATF-2 in various types of cancer
In vitro studies in human cancer cell lines, as well as in situ
studies reveal a well documented activation of JNK–p38–
ATF-2 axis in several cancer types.
Prostate cancer
Recently, a substantial number of prostate cancer patients
have been examined for phosphorylated ATF-2 expression, as
well as other downstream components of p38 pathway.
Analysis of samples from normal prostate tissue, benign
prostatic hyperplasia and advanced prostate cancer revealed
that phosphorylated ATF-2 is overexpressed in benign
prostatic hyperplasia and, more intensely, in prostate tumours.
These observations suggest that phosphorylated ATF-2
enhances survival and cell proliferation, promoting prostate
cancer progression.(32) A recent study in over 200 prostate
cancer samples showed that the expression of glucocorticoid
receptors (GR) are decreased or absent. Reconstitution of GR
expression in prostate cancer cell line LNCaP resulted in
decreased expression of MAP-kinases (MAPK) activity, such
as p38, JNK/SAPK, Mek1/2 and Erk1/2, and subsequent
downregulation of numerous transcription factors, including
ATF-2.(90) Therefore, GR acts as a tumour suppressor,
blocking ATF-2 in prostate cancer. Collectively, these data
demonstrate a possible proliferative role for ATF-2 in prostate
cancer.
Breast cancer
ATF-2 has been correlated with proliferation, invasion and
migration, as well as resistance to DNA-damaging agents in
breast cancer cell lines. In MCF-7 cells, treatment with growth
factors (estradiol, spermine) led to enhanced p38-mediated
Figure 4. Possible types of interaction between ATF-2 and other bZIP proteins in oncogenesis: interactions between bZIP molecules in
transcriptional and posttranslational levels lead to the ultimate selection of target genes that are crucial for cell proliferation, differentiation or
apoptosis. ATF-2 is dynamically involved in all these interactions. a: Regulation of transcription of other bZIP proteins, b: antagonism
for selective dimerization, leading to either transcriptionally inert or transcriptionally active dimers, c: antagonism between bZIP dimers for
binding to the same binding element, leading to activation or inactivation of transcription of the corresponding gene, d: co-operation or
equivalency between bZIP dimers for binding to the same responsive element, e: selection of the type of responsive element in crucial
genes, according to the overall cellular bZIP content.
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ATF-2 phosphorylation and subsequent increase in ATF-2
binding to the CRE element of cyclin D1 promoter.(91) More-
over in MCF10A cells, p38-activated ATF-2 targets the AP-1
site of MMP-2 and enables induction of invasive and migrative
phenotypes.(61) Furthermore, in BT474 cells, resistance to
DNA-damaging agents and, therefore, enhanced cell viability
is mediated by increase in ATF-2 transcriptional activity. In
contrast, inhibition of ATF-2 phosphorylation by a dominant
negative mutant ATF-2 decreases cell viability, after treatment
with DNA-damaging agents. However, in the latter cell line,
ATF-2 phosphorylation is JNK-dependent, rather than p38-
dependent.(40) As these experiments have been performed
in vitro, this difference could be ascribed to the different
molecular background of these cancer cell lines. A more-
attractive hypothesis is that distinct signal transduction path-
ways (p38 or JNK) may activate ATF-2 in response to different
stress stimuli, in different stages of tumour progression. The
development of in vivo study models for breast cancer
progression could clarify this issue.
In contrast, in MCF-7 cells, the promising anticancer agent
DIM (3,30-Diindolylmethane, derived from Brassica vegetables)
activates both JNK and p38 pathways, resulting in c-Jun and
ATF-2 phosphorylation, and subsequent augmentation of bind-
ing of the c-Jun–ATF-2 homodimers and heterodimers to the
proximal regulatory element of IFN-g promoter.(92) Perhaps the
type of stress signal, aswell as the presence of other ATF-2bZIP
partners are important in the selection of the kind of target gene,
apoptotic or antiapoptotic, that is ultimately activated by ATF-2.
Leukemias
ATF-2 has been implicated in differentiation-related cell-cycle
arrest and apoptosis in leukemia. In the human leukemia cell
line HL60, a combination of antioxidants with 1,25-dihydrox-
yvitamin D3 induces JNK pathway activation in differentiating
HL60 cells, followed by increased phosphorylation of c-Jun
and ATF-2.(93) Furthermore in other leukemia cell lines,
cepharanthine (CEP), a biscoclaurine alkaloid that induces
caspase-dependent apoptosis, activates p38 and its down-
stream targets c-Jun and ATF-2, but not JNK.(94) As the overall
functional impact of ATF-2 activation by these potential
anticancer agents in leukemia cells is still obscure, identifica-
tion of apoptotic or/and antiapoptotic genes activated by ATF-2
in these processes could provide more direct evidence for the
ATF-2 role in leukemia.
Tumours of the nervous system
The balance between ATF-2 and c-Jun contributes to neuronal
differentiation, cell survival and apoptosis during neuronal
development. For example, in rat pheochromocytoma PC12
cells, a well-established model for studying neuronal differ-
entiation, c-Jun protects the cells from ATF-2-mediated
apoptosis, ensuring that the neuronal differentiation will be
completed. Once the cells have been differentiated, ATF-2
acts as an executor of apoptosis.(95) Since the same
processes are generally deregulated in cancer, one could
assume that ATF-2 might also be implicated in neuroblastoma.
Indeed, experimental data have correlated ATF-2 with nervous
system tumourigenesis, indicating a possible proliferative role
in this type of cancer. In SK-N-MC and SH-SY5Y human
neuroblastoma cells, ATF-2 is potently activated by JNK
pathway.(96) Furthermore, in neuroblastoma cells N2a-b,
oncogenic Ras induces binding of ATF-2–CREB hetero-
dimers to cyclin D1 promoter, and subsequent cell prolifer-
ation. Thyroid hormone receptor represses Ras-induced
transcriptional activity of CREB and ATF-2, in response to T3
thyroid hormone.(97) Further studies, focused on role of ATF-2
in neuroblastoma, could provide more information about the
implication of this molecule in neuronal oncogenesis.
Hepatic cancer and lung cancer
A recent report demonstrates that the E2 protein of the
hepatitis C virus (HCV) can activate ATF-2 through the MAPK/
ERK pathway, thus promoting cell proliferation in human
hepatoma Huh-7 cells.(98) In addition, a study in a large
number of human lung cancer cell lines has revealed ATF-2
genetic variants in 10.6% of these cell lines, which correspond
to various histological types. Three of the five variants are
genetic polymorphisms, while the remaining two are possibly
somatic mutations.(99) These studies provide hints of positive
ATF-2 association with these types of cancer, but its exact role
remains to be elucidated.
Melanoma
Melanoma is a special skin cancer type caused by gradual
transformation of melanocytes into melanoma cells, mainly
due to exposure to UV irradiation. Late-stage melanoma cells
MeWo are highly metastatic and UV radiation-resistant. Upon
UV irradiation, ATF-2 is overexpressed in these cells and binds
to UV-Responsive Element (URE: TGACAACA) located within
promoter sequences of stress-responsive genes. A dominant
negative mutant form of ATF-2, which lacks the transactivation
domain, decreases UV-resistance, while this feature is
restored by subsequent transfection of cells with wild-type
ATF-2. Similar results are observed in the early-stage
melanoma cells WM3211 although, in this case, the metastatic
potential of melanoma cells remains unaffected.(4) This cancer
characteristic could be mediated by other CREB proteins such
as CREB, since a dominant negative CREB mutant inhibits
tumour growth and metastasis in MeWo cells.(100) Subcellular
localization of ATF-2 has been proposed as a useful
prognostic marker, since immunohistochemical staining in
melanoma specimens from 544 patients has revealed that
active nuclear ATF-2 is correlated with poor survival, whereas
inactive cytoplasmic ATF-2 is correlated with greater life
expectancy in these patients.(101)
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Mouse models in understanding
ATF-2 mode of action in carcinogenesis
Mouse study models provide invaluable in vivo evidence that
ATF-2 is closely related to skin cancer development. A recent
study showed that, in mouse skin, epidermal cells, JB6 C141,
TPA (12-0-tetradecanoylphorbol-13-acetate)-induced cell
transformation involves ATF-2, c-Jun and a novel character-
ized Serine/Threonine protein kinase, MLTK-a. MLTK-a
belongs to the MLTK (MLK-like MAP triple kinases, also
referred as Zipper sterile-a-motif kinases) family of mixed-
lineage kinases, which activate JNK, p38 and ERK kinases.
TPA promotes ATF-2 and c-Jun phosphorylation through the
MLTK-a-JNK/p38 axis. Injections with MLTK-a-overexpress-
ing JB6 C141 cells in athymic nude mice resulted in tumour
formation, while injections with si-MLTK-a-transfected cells
failed to cause tumour formation.(102)
In addition, ATF-2 is thoroughly investigated in the multi-
stage mouse skin carcinogenesis system, developed after
chemical treatment of mouse epidermis with DMBA (7,12-
dimethylbenz(a)anthracene) and TPA. This model comprises
a series of cell lines isolated from different stages of mouse
skin tumour progression, which represent distinct carcino-
genesis stages. It includes immortalized, non-tumourigenic
keratinocyte cell lines (C5N), benign papilloma cell lines (P1,
P6) as well as squamous carcinoma cell lines (B9), which give
rise to well-differentiated tumours upon injection into nude
mice. It also includes highly anaplastic, invasive spindle cell
lines (A5, CarB) which promote aggressive tumour growth and
metastasis in vivo (reviewed in Ref. 103). In this model, we
have observed a gradual increase in the levels of AP-1
components c-Jun, Fra-1, Fra-2 and ATF-2, during transition
from immortalized to invasive cell lines, while JunD levels
remained stable and JunB levels were only elevated in
squamous carcinoma cell line. Elevated JNK activity and
remarkably high levels of ATF-2 were detected in B9, A5 and
CarB cell lines, followed by increased binding and transcrip-
tional activity of ATF-2 to CRE and Jun2TRE elements.(8) We
further overexpressed a dominant negative form of ATF-2,
which cannot be phosphorylated due to 69 and 71 Thr/Ala
substitutions, but can be dimerized through its intact bZIP
domain, in the invasive spindle cell lines and assayed their
behavior in vitro and in vivo. The stable transfectants
demonstrated altered composition and decreased activity of
the AP-1 complex, followed by significant downregulation of
cyclin D1, cyclin A and ATF-3 gene targets. The dominant
negative ATF-2 transfected mice presented much smaller
tumours with an epithelial-like appearance, in comparison to
control mice, which were injected with parental or empty
vector-transfected cells. Conclusively, aggressive character-
istics were suppressed in the dnATF-2 transfected mice,
indicating that ATF-2 overexpression is required for tumour
growth and progression in mouse skin oncogenesis.(9) The
fact that ATF-2 levels are significantly elevated in more-
aggressive mouse skin carcinogenesis stages, as well as the
observation that dnATF-2 altered the oncogenic potential of
these cells indicates that, among all bZIP proteins, ATF-2 has
the key role in the advanced stages of this process.(9)
Collectively, these results demonstrate a proliferative role
for ATF-2 in skin cancer progression, in response to JNK or/
and p38 activation. c-Jun seems to be an essential co-operator
for ATF-2 during this process.
A theoretical basis for inhibition of ATF-2-
promoted proliferation in cancer
Based on the findings in mouse study models, we can propose
a model of ATF-2-promoted proliferation in skin carcino-
genesis upon chemical treatment (see Fig. 5A), as well as a
theoretical basis for its inhibition (see Fig. 5B). The initiating
step in this process seems to be DMBA-promoted mutations in
the ras gene. Constant activation of the Ras pathway, results in
permanent phosphorylation of downstream kinases p38, JNK
and ERK. c-Jun and ATF-2 are subsequently phosphorylated
and form homodimers or/and heterodimers that bind to
Jun2TRE element, enhancing c-jun transcription, as well as
to CRE elements, enhancing transcription of genes that
enable cell cycle progression and cell proliferation (e.g. cyclin
A, cyclin D1, ATF-3). As carcinogenesis proceeds, over-
expession of these crucial genes contributes to acquisition of
more-aggressive cancer characteristics (see Fig. 5A).
Upon dnATF-2 transfection, antagonism between wild-type
ATF-2 and mutant ATF-2 takes place at two distinct levels:
First, mutant ATF-2 abrogates the wild-type ATF-2 phosphor-
ylation by occupying the MAP kinases’ active site. Second,
mutant ATF-2 proteins form inactive dnATF-2–c-Jun or/and
dnATF-2–ATF-2 heterodimers, which bind to gene target
promoters, but they are incapable of activating them. There-
fore, transcription of cyclin A, cyclin D, ATF-3 as well as
enhancement of c-jun is suppressed, leading to cell-cycle
arrest and abolishment of cell proliferation (see Fig. 5B).
Thus, the use of dnATF-2 in targeting against ATF-2 could
block proliferation of cancer cells in skin tumours. This
approach might possibly be applicable to a range of cancer
types, such as melanoma,(4) breast cancer,(40) or even other
types where ATF-2 presents a well-documented proliferative
role; however, in vivo models are essential in order to test if this
generalization holds true.
Future perspectives
On the one hand, significant in vitro and in situ experiments
demonstrate mainly a proliferative role for ATF-2 in several
types of cancer, although studies in other cancer types, e.g.
leukemia, argue against this role. On the other hand, robust in
vivo evidence from mouse study models positively correlates
ATF-2 with cancer progression. The fact that ATF-2 function
is affected by selective dimerizations with other bZIP proteins
may explain the controversial ATF-2 effects, since different
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bZIP content in different tissues could result in either
proliferative or anti-proliferative ATF-2 effect during carcino-
genesis. Perhaps, the most-fruitful approach in studying not
only ATF-2, but also several other ATF/CREB proteins with a
highly controversial role in oncogenesis would be in relation
with its dimerizing partners.
An emerging bZIP family interplay in both transcriptional
and posttranslational levels involves complex interactions of
bZIP proteins based on regulation of transcription of bZIP
proteins by other bZIP dimers, selective dimerizations as well
as different binding affinities of bZIP dimers for responsive
elements (see Fig. 4). These interactions might serve as a
potential sophisticated, overall mechanism of differential gene
activation, which enables cell homeostasis. The fact that ATF-
2 participates in all these types of interaction implies a key role
as a modifier of processes that are generally deregulated in
cancer, i.e. differentiation, proliferation and apoptosis.
ATF-2 represents the last molecule in the Ras-activated
p38/JNK cascade, which not only has the ability to select the
final target genes according to its upstream signals, but also
to dynamically affect the bZIP protein composition in the cell
and to modify bZIP interactions. Thus, it could serve as a
molecular target in cancer therapy, at least for the subset of
cancers where its proliferative role is well documented. In
Ras-promoted carcinogenesis, dominant negative ATF-2
could be used in order to block proliferation of cancer cells.
Since dominant negative ATF-2 has been shown to
efficiently inhibit cell proliferation in mouse skin cancer, as
well as in human breast cancer and melanoma, it might prove
to be a promising anticancer agent for these types of cancer.
A recent in silico analysis providing evidence that ATF-2 is
likely to be targeted by microRNAs adds a fascinating
perspective in development of therapeutic agents against
ATF-2.(104) Blocking peptides of ATF-2(105) could also be
considered as a source for pharmacomimetic drug design.
Combination of ATF-2 blocking together with its upstream
kinases’ inhibition could dramatically increase the degree of
cell cycle arrest and apoptosis. Furthermore, anticancer
Figure 5. Model of ATF-2 action stimulated by oncogenic Ras and its inhibition. A: Downstream kinases p38, JNK and ERK
phosphorylate c-Jun and ATF-2. c-Jun–ATF-2 heterodimers activate cyclin A, cyclin D1 and ATF-3, which contribute to acquisition of more
aggressive cancer characteristics.B:. Effect of dominantnegative ATF-2 in mouse skin oncogenesis:dnATF-2 antagonizeswild-typeATF-2
for binding to the MAPKs’ active site. Then, mutant ATF-2 forms inactive homodimers or heterodimers with c-Jun, thus suppressing
transcription of gene targets and leading to arrest of cell-cycle progression and cell proliferation.
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therapy might generally be benefit not only by ATF-2
blocking, but also by favoring synthesis of those bZIP
proteins that form inert dimers with ATF-2, c-jun or/
and other bZIP proteins with a proved proliferative role,
thus altering bZIP protein interactions towards an antiproli-
ferative or apoptotic cellular bZIP status. Future studies
towards the directions mentioned above may facilitate the
planning of successful treatment protocols against the
disease.
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